Michael Heneka to Tauopathies
This is a "connection" page, showing publications Michael Heneka has written about Tauopathies.
Connection Strength
1.650
-
Ising C, Heneka MT. Chronic inflammation: a potential target in tauopathies. Lancet Neurol. 2023 05; 22(5):371-373.
Score: 0.834
-
Karabag D, Heneka MT, Ising C. The putative contribution of cellular senescence to driving tauopathies. Trends Immunol. 2024 Oct; 45(10):837-848.
Score: 0.230
-
Karabag D, Scheiblich H, Griep A, Santarelli F, Schwartz S, Heneka MT, Ising C. Characterizing microglial senescence: Tau as a key player. J Neurochem. 2023 08; 166(3):517-533.
Score: 0.210
-
Perea JR, Bol?s M, Cuadros R, Garc?a E, Garc?a-Escudero V, Hern?ndez F, McManus RM, Heneka MT, Avila J. p38 Inhibition Decreases Tau Toxicity in Microglia and Improves Their Phagocytic Function. Mol Neurobiol. 2022 Mar; 59(3):1632-1648.
Score: 0.190
-
Jiang S, Maphis NM, Binder J, Chisholm D, Weston L, Duran W, Peterson C, Zimmerman A, Mandell MA, Jett SD, Bigio E, Geula C, Mellios N, Weick JP, Rosenberg GA, Latz E, Heneka MT, Bhaskar K. Proteopathic tau primes and activates interleukin-1? via myeloid-cell-specific MyD88- and NLRP3-ASC-inflammasome pathway. Cell Rep. 2021 09 21; 36(12):109720.
Score: 0.187